This concept has been supported by clinical findings in esophageal cancer, where dual inhibition of TIGIT and PD - 1 achieved improved objective response rate (ORR, 27.8%) and disease control rate (DCR, 50%) in immunotherapy-naïve patients (33.3% of whom had adenocarcinoma) (22). Here, RPL17 is linked to esophageal cancer.